Clinical Trial Update: A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating safinamide for cognitive impairment in Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease with Cognitive Impairment

Drugs mentioned

• Safinamide (Safinamide)

Snippet

Sponsor: Newron Pharmaceuticals SPA | Conditions: Parkinson's Disease With Cognitive Impairments | Phase 2 | Status: COMPLETED